IP Library Granted Patent US 11,479,761
Granted Patent B2
US 11,479,761 · App. 16/400,021 · Granted Oct 25, 2022

Nuclease-mediated genome editing

Inventor: John Van Der Oost (Renkum, NL)
Assignee: WAGENINGEN UNIVERSITEIT
C12N9/22C12N15/11C07K2319/09C12N2310/20
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,479,761
App. No.
16/400,021
Granted
Oct 25, 2022
Kind
B2
Abstract

The invention relates to the field of genetic engineering tools, methods and techniques for gene or genome editing. Specifically, the invention concerns isolated polypeptides having nuclease activity, host cells and expression vectors comprising nucleic acids encoding said polypeptides as well as methods of cleaving and editing target nucleic acids in a sequence-specific manner. The polypeptides, nucleic acids, expression vectors, host cells and methods of the present invention have application in many fields of biotechnology, including, for example, synthetic biology and gene therapy.

Claims (7)

1. An in vitro method for targeting a target nucleic acid, the method comprising contacting a composition comprising the target nucleic acid with a CRISPR complex comprising (a) a Cpf1 polypeptide that comprises a RuvC-like domain and does not comprise an HNH domain and (b) an engineered guide RNA that is capable of directing sequence-specific binding of the complex to the target nucleic acid, wherein the Cpf1 polypeptide comprises an amino acid sequence at least 98% identical to SEQ ID NO:1 and has nuclease activity.

2. The method of claim 1 , wherein the Cpf1 polypeptide comprises at least one mutation compared to the polypeptide of SEQ ID NO:l.

3. The method of claim 1 , wherein the Cpf1 polypeptide is associated with one or more heterologous functional domains.

4. The method of claim 1 , wherein the target nucleic acid is in a eukaryotic cell.

5. The method of claim 1 , wherein the target nucleic acid is cleaved.

6. The method of claim 1 , wherein a gene product is modified or the amount or expression of a gene product is modified.

7. The method of claim 1 , wherein the target nucleic acid comprises a disease-causing genetic mutation.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 23, 2020
From: VAN DER OOST, JOHN
To: WAGENINGEN UNIVERSITEIT
Reel/Frame 053854/0740 →
Priority Claims (1)
GB 1506509 · Apr 16, 2015 · national
Continuity (4)
Continuation 15566528
Provisional Application 62269143 · Dec 18, 2015
Provisional Application 62312724 · Mar 24, 2016
Related Publication 20200010817A1 · Jan 9, 2020